Kidney Week

Abstract: FR-PO0253

Effects of Switching from Etelcalcetide to Upacicalcet in Patients on Hemodialysis with Secondary Hyperparathyroidism

Session Information

• Bone and Mineral Metabolism: Clinical Epidemiology and Outcomes
  November 07, 2025 | Location: Exhibit Hall, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Bone and Mineral Metabolism

• 502 Bone and Mineral Metabolism: Clinical

Authors

• Sato, Eiichi, Shinmatsudo Central General Hospital, Matsudo, Chiba, Japan

Eiichi Sato, MD, PhD

• Urata, Miyako, Shinmatsudo Central General Hospital, Matsudo, Chiba, Japan

Miyako Urata, MD

• Sato, Shohei, Shinmatsudo Central General Hospital, Matsudo, Chiba, Japan

Shohei Sato, MD

• Ono, Takao, Shinmatsudo Central General Hospital, Matsudo, Chiba, Japan

Takao Ono, MD

• Degawa, Manaka, Shinmatsudo Central General Hospital, Matsudo, Chiba, Japan

Manaka Degawa, MD

• Kojima, Shiori, Shinmatsudo Central General Hospital, Matsudo, Chiba, Japan

Shiori Kojima, MD

• Lu, Hongmei, Shinmatsudo Central General Hospital, Matsudo, Chiba, Japan

Hongmei Lu, MD

• Nomura, Mayumi, Shinmatsudo Central General Hospital, Matsudo, Chiba, Japan

Mayumi Nomura, MD

• Matsumura, Daisuke, Shinmatsudo Central General Hospital, Matsudo, Chiba, Japan

Daisuke Matsumura, MD

• Moriyama, Noriaki, Shinmatsudo Central General Hospital, Matsudo, Chiba, Japan

Noriaki Moriyama, MD

• Amaha, Mayuko, Shinmatsudo Central General Hospital, Matsudo, Chiba, Japan

Mayuko Amaha, MD

• Ueda, Yoshihiko, Dokkyo Medical University, Saitama Medical Center, Koshigaya, Saitama prefecture, Japan

Yoshihiko Ueda, MD, PhD

• Nakamura, Tsukasa, Kashiwa Forest Clinic, Kashiwa, Chiba Prefecture, Japan

Tsukasa Nakamura

Background

No English-language research papers have reported on the clinical use of upacicalcet, a novel intravenous calcimimetic agent for the treatment of secondary hyperparathyroidism (SHPT) in hemodialysis patients. Therefore, this study aimed to investigate the outcomes of switching from etelcalcetide to upacicalcet.

Methods

The subjects included 37 hemodialysis patients with SHPT treated with etelcalcetide before switching to upacicalcet. This study was a single-center retrospective study conducted in Japan. Serum levels of corrected calcium (Ca), phosphorus (P), intact parathyroid hormone (iPTH), and the dose of maxacalcitol were assessed at three and six months after switching to upacicalcet.

Results

As a result of the switch from etelcalcetide to upacicalcet, the serum corrected Ca level remained unchanged, from 8.9 ± 0.6 mg/dL to 9.1 ± 0.7 mg/dL (p = 0.104) at three months and to 9.0 ± 0.6 mg/dL (p = 0.197) at six months. Meanwhile, the serum P level decreased from 6.3 ± 1.5 mg/dL to 5.8 ± 1.5 mg/dL (p = 0.069) at three months and to 5.9 ± 1.9 mg/dL (p = 0.039) at six months. The iPTH level increased slightly, from 153.8 ± 100.3 pg/mL to 176.4±124.6 pg/mL (p = 0.337) at three months and to 206.5 ± 168.7 pg/mL (p = 0.017) at six months. Multiple regression analysis revealed that the change in iPTH was related to the change in P levels.

Conclusion

These findings suggested that upacicalcet may be a useful option for managing serum P levels in hemodialysis patients with SHPT.

Digital Object Identifier (DOI)

• doi: 10.1681/ASN.202572tchxwj